Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PfSPZ-LARC2 Vaccine in Malaria-exposed Adults and Children in Burkina Faso
NCT06652737Phase 1Completed
- Sponsor
- Sanaria Inc.
- Start
- Mar 2025
- Primary completion
- Feb 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PfSPZ-LARC2 in malaria (10 cohorts), sponsored by Sanaria Inc. Primary endpoints: Number of trial participants with presence of breakthrough blood stage infection at 28 days, Incidence of related grade 3 solicited and unsolicited adverse events (AEs) at 28 days and 2 more. Started Mar 2025; status: completed.
02
Drugs
PfSPZ-LARC2
03
Conditions
malaria
Beyond the preview
Go deeper on NCT06652737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06652737.